Aspirin

Generic Name
Aspirin
Brand Names
Aggrenox, Alka-seltzer, Alka-seltzer Fruit Chews, Anacin, Arthriten Inflammatory Pain, Ascomp, Aspi-cor, Aspir-low, Bayer Aspirin, Bayer Womens, Bc Arthritis, Bc Original Formula, Bufferin, Duoplavin, Durlaza, Ecotrin, Ecpirin, Endodan Reformulated May 2009, Equagesic, Exaprin, Excedrin, Excedrin PM Triple Action, Fasprin, Fiorinal, Goody's Body Pain, Goody's Extra Strength, Goody's PM, Miniprin, Norgesic, Norgesic Forte, Orphengesic, Pamprin Max Formula, Robaxisal, ST. Joseph Aspirin, Stanback Headache Powder Reformulated Jan 2011, Trianal, Trianal C, Vanquish, Vazalore, Yosprala
Drug Type
Small Molecule
Chemical Formula
C9H8O4
CAS Number
50-78-2
Unique Ingredient Identifier
R16CO5Y76E
Background

Also known as Aspirin, acetylsalicylic acid (ASA) is a commonly used drug for the treatment of pain and fever due to various causes. Acetylsalicylic acid has both anti-inflammatory and antipyretic effects. This drug also inhibits platelet aggregation and is used in the prevention of blood clots stroke, and myocardial infarction (MI) .

Interestingly, the results of various studies have demonstrated that long-term use of acetylsalicylic acid may decrease the risk of various cancers, including colorectal, esophageal, breast, lung, prostate, liver and skin cancer . Aspirin is classified as a non-selective cyclooxygenase (COX) inhibitor and is available in many doses and forms, including chewable tablets, suppositories, extended release formulations, and others .

Acetylsalicylic acid is a very common cause of accidental poisoning in young children. It should be kept out of reach from young children, toddlers, and infants .

Indication

Pain, fever, and inflammation

Acetylsalicylic acid (ASA), in the regular tablet form (immediate-release), is indicated to relieve pain, fever, and inflammation associated with many conditions, including the flu, the common cold, neck and back pain, dysmenorrhea, headache, tooth pain, sprains, fractures, myositis, neuralgia, synovitis, arthritis, bursitis, burns, and various injuries. It is also used for symptomatic pain relief after surgical and dental procedures .

The extra strength formulation of acetylsalicylic acid is also indicated for the management migraine pain with photophobia (sensitivity to light) and phonophobia (sensitivity to sound).

Other indications

ASA is also indicated for various other purposes, due to its ability to inhibit platelet aggregation. These include:

Reducing the risk of cardiovascular death in suspected cases of myocardial infarction (MI) .

Reducing the risk of a first non-fatal myocardial infarction in patients, and for reducing the risk of morbidity and mortality in cases of unstable angina and in those who have had a prior myocardial infarction .

For reducing the risk of transient ischemic attacks (TIA) and to prevent atherothrombotic cerebral infarction (in conjunction with other treatments) .

For the prevention of thromboembolism after hip replacement surgery .

For decreasing platelet to platelet adhesion following carotid endarterectomy, aiding in the prevention of transient ischemic attacks (TIA) .

Used for patients undergoing hemodialysis with a silicone rubber arteriovenous cannula inserted to prevent thrombosis at the insertion site .

Important note regarding use of the extended-release formulation

In the setting of acute myocardial infarction, or before percutaneous interventions, the extended-release form of acetylsalicylic acid should not be used. Use immediate-release formulations in scenarios requiring rapid onset of action . The extended-release form is taken to decrease the incidence of mortality and myocardial infarction (MI) for individuals diagnosed with chronic coronary artery disease (CAD), including patients with previous myocardial infarction (MI) or unstable angina or with chronic stable angina. Additionally, the extended-release form is used to decrease the risk of death and recurrent episodes of stroke in patients with a history of stroke or TIA .

Associated Conditions
Acute Coronary Syndrome (ACS), Anxiety, Atherothrombotic cerebral infarction, Cardiovascular Disease (CVD), Cardiovascular Events, Cardiovascular Mortality, Colorectal Adenomas, Colorectal Cancer, Common Cold, Coronary artery reocclusion, Death, Dyspeptic signs and symptoms, Fever, Flu caused by Influenza, Headache, Heterozygous Familial Hypercholesterolemia (HeFH), Inflammation, Juvenile Idiopathic Arthritis (JIA), Major Adverse Cardiovascular and Cerebrovascular Events (MACCE), Menstrual Pain, Migraine, Morbidity, Mucocutaneous Lymph Node Syndrome, Muscle Contraction, Myalgia, Myocardial Infarction, Myocardial Infarction (MI), first occurrence, Neuropathic Pain, Pain, Pain caused by Common Cold, Pain caused by Rheumatism, Pericarditis, Polycythemia Vera (PV), Pre-Eclampsia, Rheumatism, Rheumatoid Arthritis, Rhino Sinusitis, Severe Pain, Spondyloarthropathies, Stroke, Systemic Lupus Erythematosus, Tension Headache, Thromboembolism, Thrombosis, Toothache, Transient Ischemic Attack, Vascular Death, Venous Thromboembolism, Acute Inflammation, Articular inflammation, Atherothrombotic events, Death caused by Myocardial Infarction, Fever or influenza-like illness, Moderate Pain, Recurrent Ischemic Stroke
Associated Therapies
Anti-platelet Therapy, Hemodialysis Treatment, Secondary Prevention

Additional Benefit of Cilostazol to Dual Antiplatelet Therapy After Biolimus-eluting Stent Implantation

First Posted Date
2010-09-01
Last Posted Date
2016-11-15
Lead Sponsor
Yonsei University
Target Recruit Count
630
Registration Number
NCT01192724
Locations
🇰🇷

Wonju Christian Hospital, Wonju, Gangwon, Korea, Republic of

A Study of Aleglitazar in Combination With Aspirin in Healthy Volunteers

First Posted Date
2010-08-25
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
44
Registration Number
NCT01188304

Aspirin and Plavix Following Coronary Artery Bypass Grafting

First Posted Date
2010-07-08
Last Posted Date
2015-05-19
Lead Sponsor
Ahmad Slim
Target Recruit Count
20
Registration Number
NCT01158703
Locations
🇺🇸

Brooke Army Medical Center, San Antonio, Texas, United States

A Registry To Evaluate Safety And Effectiveness Of Everolimus Drug Eluting Stent For Coronary Revascularization

Phase 4
Conditions
First Posted Date
2010-07-07
Last Posted Date
2010-07-12
Lead Sponsor
CCRF Consulting Co., Ltd.
Target Recruit Count
1900
Registration Number
NCT01157455
Locations
🇨🇳

Fuwai Hospital, Beijing, China

Reproducibility and Comparison of Platelet Function Assays With Aspirin and Clopidogrel (MK-0000-167)

First Posted Date
2010-04-22
Last Posted Date
2015-08-13
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
15
Registration Number
NCT01108588

Clopidogrel/Aspirin Interaction Study

Phase 4
Completed
Conditions
Interventions
First Posted Date
2010-04-13
Last Posted Date
2015-04-28
Lead Sponsor
Population Health Research Institute
Target Recruit Count
82
Registration Number
NCT01102439
Locations
🇨🇦

Population Health Research Institute, Hamilton, Ontario, Canada

Effects of Urocortins on Forearm Arterial Blood Flow in Healthy Volunteers (Protocol 3)

First Posted Date
2010-03-31
Last Posted Date
2012-05-15
Lead Sponsor
University of Edinburgh
Target Recruit Count
10
Registration Number
NCT01096706
Locations
🇬🇧

Wellcome Trust Clinical Research Facility, Royal Infirmary of Edinburgh, Edinburgh, Mid Lothian, United Kingdom

A Study Assessing Inhibition of Serum Thromboxane B2 Levels With PN400 and Low Dose Aspirin

Phase 1
Completed
Conditions
Interventions
First Posted Date
2010-03-29
Last Posted Date
2010-12-07
Lead Sponsor
AstraZeneca
Target Recruit Count
40
Registration Number
NCT01094483
Locations
🇺🇸

Research Site, Overland Park, Kansas, United States

B-Lymphocyte Immunotherapy in Islet Transplantation for Initial Islet Graft Failure

First Posted Date
2010-01-14
Last Posted Date
2014-06-11
Lead Sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
Registration Number
NCT01049633
Locations
🇺🇸

Hospital of the University of Pennsylvania, Philadelphia, Pennsylvania, United States

ThrombElastoGraphic Haemostatic Status and Antiplatelet Therapy After Coronary Artery Bypass Graft Surgery

First Posted Date
2010-01-12
Last Posted Date
2013-09-24
Lead Sponsor
Rigshospitalet, Denmark
Target Recruit Count
250
Registration Number
NCT01046942
Locations
🇩🇰

Dep. of cardiothoracic surgery, Rigshospitalet, Copenhagen, Kbh, Denmark

© Copyright 2024. All Rights Reserved by MedPath